RT Journal Article
SR Electronic
T1 Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.24.24310961
DO 10.1101/2024.07.24.24310961
A1 Naeem, Fawaz
A1 Leone, Teresa C.
A1 Petucci, Christopher
A1 Shoffler, Clarissa
A1 Kodihalli, Ravindra C.
A1 Hidalgo, Tiffany
A1 Tow-Keogh, Cheryl
A1 Mancuso, Jessica
A1 Tzameli, Iphigenia
A1 Bennett, Donald
A1 Groarke, John D.
A1 Roth Flach, Rachel J.
A1 Rader, Daniel J.
A1 Kelly, Daniel P.
YR 2024
UL http://medrxiv.org/content/early/2024/07/25/2024.07.24.24310961.abstract
AB Background Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop HF disease phenotype-specific approaches to define and guide treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and extend existing knowledge of the plasma metabolic signatures in human HF.Methods Quantitative, targeted LC/MS plasma metabolomics was conducted on 787 samples collected by the Penn Medicine BioBank from subjects with HFrEF (n=219), HFpEF (n=357), and matched non-failing Controls (n=211). A total of 90 metabolites were analyzed, comprising 28 amino acids, 8 organic acids, and 54 acylcarnitines. 733 of these samples were also processed via an OLINK protein panel for proteomic profiling.Results Consistent with previous studies, unsaturated forms of medium/long chain acylcarnitines were elevated in the HFrEF group to a greater extent than the HFpEF group compared to Controls. A number of amino acid derivatives, including 1- and 3-methylhistidine, homocitrulline, and symmetric (SDMA) and asymmetric (ADMA) dimethylarginine were elevated in HF, with ADMA elevated uniquely in HFpEF. Plasma branched-chain amino acids (BCAA) were not different across the groups; however, short-chain acylcarnitine species indicative of BCAA catabolism were significantly elevated in both HF groups. The ketone body 3-hydroxybutyrate (3-HBA) and its metabolite C4-OH carnitine were uniquely elevated in the HFrEF group. Linear regression models demonstrated a significant correlation between plasma 3-HBA and NT-proBNP in both forms of HF, stronger in HFrEF.Conclusions These results identify plasma signatures that are shared as well as potentially distinguish between HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming in extra-cardiac tissues were identified as unique signatures in the HFrEF group, possibly related to the lipolytic action of increased levels of BNP. Future studies will be necessary to further validate these metabolites as HF biosignatures that may guide phenotype-specific therapeutics and provide insight into the systemic metabolic responses to HFpEF and HFrEF.What Is New?“Real world” targeted metabolomic profiling on wide range of metabolites in a diverse population of patients with HFrEF and HFpEF.Levels of 3-hydroxybutyrate and its metabolite C4OH-carnitine were uniquely increased in the HFrEF group and correlated with levels of plasma NT-proBNP in both the heart failure groups, indicating the possibility of a heart-adipose-liver axis.Asymmetric dimethylarginine, a known inhibitor of nitric oxide synthase, was uniquely upregulated in HFpEF suggesting that there may also be an underlying component of vascular dysregulation contributing to HFpEF pathophysiology.What Are the Clinical Implications?The plasma metabolomic changes seen in the heart failure cohorts support the existing theory of metabolic reprogramming, providing further rationale for the pursuit of therapeutic targets for the treatment of heart failure.Quantitative metabolomic profiling shows promise for guiding therapeutic decisions in HFrEF and HFpEF.Modulation of natriuretic peptides may enhance the delivery of ketone and fatty acids to the “fuel starved” failing heart.Competing Interest StatementDr. Kelly received research support from Pfizer and is a paid consultant for Pfizer.Clinical TrialThis is not a clinical trial.Funding StatementDPK was supported by NIH R01 HL151345, R01 HL128349 (DPK) and Pfizer Co, Research Support. Pfizer paid the Penn Metabolomics Core (fee-for-service) for studies that were performed in this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PennMedicine BioBank is approved under IRB protocol# 813913 at the University of Pennsylvania.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.